Introduction
Half-life is one of the most important pharmacokinetic parameters for research peptides. It determines how long a peptide remains active in a biological system, how frequently it must be administered in research protocols, and how to interpret the timing of effects relative to administration. This guide explains what half-life means, what determines it for peptides, and how it should shape research protocol design.
What Is Half-Life?
Biological half-life (t½) is the time required for the plasma concentration of a compound to decrease by 50% following administration. If a peptide has a half-life of 2 hours, its plasma concentration at 2 hours post-injection is half what it was at peak. At 4 hours, it is 25% of peak. At 6 hours, 12.5% of peak. After approximately 5 half-lives, a compound is considered essentially eliminated (less than 3% of peak concentration remains). Half-life determines both the duration of action and the accumulation behavior with repeated dosing.
What Determines Peptide Half-Life?
Peptide half-life is determined by the interplay of three elimination processes. Renal filtration: small peptides below approximately 50 kDa are filtered by the kidneys and excreted in urine. Smaller peptides are cleared faster through this route. Metabolic degradation: serum and tissue peptidases cleave peptide bonds, inactivating the compound. The rate depends on the peptide’s specific sequence and susceptibility to the peptidases present. Receptor-mediated internalization: some peptides are cleared through internalization with their receptor. The relative contribution of each process varies by peptide.
Half-Life Range Across Research Peptides
Research peptides span an enormous range of half-lives. Native GLP-1 is approximately 2 minutes — essentially a local gut signal. Native GHRH is approximately 5 to 10 minutes. Ipamorelin is approximately 2 hours. BPC-157 is approximately 4 hours. CJC-1295 without DAC is approximately 30 minutes. Semaglutide is approximately 7 days. CJC-1295 with DAC is 6 to 8 days. This 5,000-fold range reflects the diversity of modification strategies employed and has profound practical implications for protocol design.
How Half-Life Affects Protocol Design
Short half-life peptides require frequent administration to maintain active concentrations. For BPC-157 research protocols, multiple daily administrations are typical in animal studies. For CJC-1295 with DAC, weekly administration is sufficient. The pulsatile nature of GH secretion means that for GH axis research using short-acting GHRPs and GHRH analogues, the timing of administration relative to measurement windows matters enormously — you need to know whether the peptide’s active window aligns with your endpoint measurement time.
Steady State and Accumulation
With repeated dosing, a peptide reaches steady-state plasma concentration after approximately 5 half-lives. For long-acting peptides like CJC-1295 with DAC (half-life ~7 days), steady state is not reached until approximately 5 weeks of weekly dosing. For short-acting peptides, steady state may be reached within hours of beginning a dosing regimen. Designing chronic research protocols requires accounting for whether steady state has been reached before the measurement period.
Measuring Half-Life
Half-life is measured through pharmacokinetic studies in which the peptide is administered and blood samples are collected at multiple time points to measure plasma concentrations. Plotting concentration versus time and fitting a pharmacokinetic model gives the elimination half-life. Published half-life data for research peptides should be evaluated in context — half-life can vary between species, routes of administration, dose, and individual biological variability.
Conclusion
Half-life is a fundamental pharmacokinetic parameter that must be understood for any research peptide protocol. It determines dosing frequency, the timing of measurement relative to administration, steady-state behavior with repeated dosing, and the duration of receptor occupancy. Matching protocol design to the half-life characteristics of the research compound is essential for generating interpretable and reproducible data.